Would the Bayer-Baby Aspirin scenario be the model sales/distribution that Amarin should emulate. How did Bayer get everyone in the world to know of the heart benefits of aspirin. And recent guidelines say that it is still beneficial to all with any suspicion of CVD.
What are suggestions for initiating some kind of "bottoms up" groundswell of recognition among the general populace. The "top down" approach doesn't seem to be working. Dave
If you extrapolate the compounding effects of multiple 'boosters'... its not hard to conclude who could suffer the most: seniors. Hmmm...(thinking out loud).. did someone realize the baby boomers were going to overstress social security funds and Medicare spending? Those expenses drop dramatically in such a nightmarish outcome.
News 
Market Data 
Discover 
